Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2021
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac, Tanja Fauti, Johannes Sam, et al.
Nature Communications
|
June 11, 2026
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma
Andrea Di Pietro, Lewis Au, Patrick Crock, et al.
The Journal of Clinical Investigation
|
May 23, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
Cancer Research
|
May 16, 2020
The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
Christoph M Griessinger, Tove Olafsen, Alessandro Mascioni, et al.
Oncoimmunology
|
April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Mabs
|
May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Inja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Cancer Cell
|
March 7, 2017
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, et al.
Nature
|
September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8<sup>+</sup> T cells
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Molecular Cancer Therapeutics
|
August 2, 2022
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Raffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2021
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac, Tanja Fauti, Johannes Sam, et al.
Nature Communications
|
June 11, 2026
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma
Andrea Di Pietro, Lewis Au, Patrick Crock, et al.
The Journal of Clinical Investigation
|
May 23, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
Cancer Research
|
May 16, 2020
The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
Christoph M Griessinger, Tove Olafsen, Alessandro Mascioni, et al.
Oncoimmunology
|
April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Mabs
|
May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Inja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Cancer Cell
|
March 7, 2017
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, et al.
Nature
|
September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8<sup>+</sup> T cells
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Molecular Cancer Therapeutics
|
August 2, 2022
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Raffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol, et al.
Page
of 8